Cargando…

History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic

To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Meybeck, Agnès, Huleux, Thomas, Tétart, Macha, Thill, Pauline, Derdour, Vincent, Bocket, Laurence, Alidjinou, Enagnon Kazali, Patoz, Pierre, Robineau, Olivier, Ajana, Faiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705918/
https://www.ncbi.nlm.nih.gov/pubmed/34946093
http://dx.doi.org/10.3390/microorganisms9122491
_version_ 1784622065171562496
author Meybeck, Agnès
Huleux, Thomas
Tétart, Macha
Thill, Pauline
Derdour, Vincent
Bocket, Laurence
Alidjinou, Enagnon Kazali
Patoz, Pierre
Robineau, Olivier
Ajana, Faiza
author_facet Meybeck, Agnès
Huleux, Thomas
Tétart, Macha
Thill, Pauline
Derdour, Vincent
Bocket, Laurence
Alidjinou, Enagnon Kazali
Patoz, Pierre
Robineau, Olivier
Ajana, Faiza
author_sort Meybeck, Agnès
collection PubMed
description To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed a SARS-CoV-2 serology. Among the 600 PLWHIV included, 16 have been infected with SARS-CoV-2. Symptoms consistent with COVID-19 were frequent both in SARS-CoV-2 positive and negative patients (67% vs. 32%, p = 0.02). Among SARS-CoV-2 infected patients, one (6%) has been hospitalized and five (31%) have been asymptomatic. Close contact with a confirmed COVID-19 case was the only factor associated with COVID-19 acquisition (40% vs. 13%, p = 0.01). The prevalence of COVID-19 in PLWHIV was 2.5%, half of the overall population estimate after the first wave of the pandemic in France. In conclusion, proportion of asymptomatic COVID-19 was high in PLWHIV. The prevalence of COVID-19 in PLWHIV was two times lower than in the general population.
format Online
Article
Text
id pubmed-8705918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87059182021-12-25 History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic Meybeck, Agnès Huleux, Thomas Tétart, Macha Thill, Pauline Derdour, Vincent Bocket, Laurence Alidjinou, Enagnon Kazali Patoz, Pierre Robineau, Olivier Ajana, Faiza Microorganisms Article To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed a SARS-CoV-2 serology. Among the 600 PLWHIV included, 16 have been infected with SARS-CoV-2. Symptoms consistent with COVID-19 were frequent both in SARS-CoV-2 positive and negative patients (67% vs. 32%, p = 0.02). Among SARS-CoV-2 infected patients, one (6%) has been hospitalized and five (31%) have been asymptomatic. Close contact with a confirmed COVID-19 case was the only factor associated with COVID-19 acquisition (40% vs. 13%, p = 0.01). The prevalence of COVID-19 in PLWHIV was 2.5%, half of the overall population estimate after the first wave of the pandemic in France. In conclusion, proportion of asymptomatic COVID-19 was high in PLWHIV. The prevalence of COVID-19 in PLWHIV was two times lower than in the general population. MDPI 2021-12-01 /pmc/articles/PMC8705918/ /pubmed/34946093 http://dx.doi.org/10.3390/microorganisms9122491 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Meybeck, Agnès
Huleux, Thomas
Tétart, Macha
Thill, Pauline
Derdour, Vincent
Bocket, Laurence
Alidjinou, Enagnon Kazali
Patoz, Pierre
Robineau, Olivier
Ajana, Faiza
History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
title History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
title_full History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
title_fullStr History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
title_full_unstemmed History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
title_short History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
title_sort history of covid-19 symptoms and seroprevalence of sars-cov-2 antibodies in hiv-infected patients in northern france after the first wave of the pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705918/
https://www.ncbi.nlm.nih.gov/pubmed/34946093
http://dx.doi.org/10.3390/microorganisms9122491
work_keys_str_mv AT meybeckagnes historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT huleuxthomas historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT tetartmacha historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT thillpauline historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT derdourvincent historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT bocketlaurence historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT alidjinouenagnonkazali historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT patozpierre historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT robineauolivier historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic
AT ajanafaiza historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic